Breaking Finance News

Biogen Inc (NASDAQ:BIIB) target price raised to $343.10, reported today by Vetr Inc.

Biogen Inc (NASDAQ:BIIB) had its target price raised to $343.10 by Vetr Inc. in a report released 9/29/2016. The new target price indicates a possible upside of 0.12% based on the company's last stock close price.

Previously on Wednesday September 21, 2016, Vetr Inc. reported about Biogen Inc (NASDAQ:BIIB) raised the target price from $0.00 to $346.47. At the time, this indicated a possible upside of 0.12%.

Yesterday Biogen Inc (NASDAQ:BIIB) traded -1.54% lower at $305.78. The company’s 50-day moving average is $309.21 and its 200-day moving average is $277.22. The last stock close price is up 10.30% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,133,926 shares of the stock were exchanged, down from an average trading volume of 1,728,190

See Chart Below

Biogen Inc (NASDAQ:BIIB)

Biogen Inc has a 52 week low of $223.02 and a 52 week high of $333.65 with a P/E ratio of 17.86 The company’s market cap is currently $0.

In addition to Vetr Inc. reporting its target price, a total of 19 firms have reported on the stock. The consensus target price is $333.47 with 6 firms rating the stock a strong buy, 8 firms rating the stock a buy, 9 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Biogen Inc (NASDAQ:BIIB)

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.